Ghost Tree Capital’s Cogent Biosciences COGT Stock Holding History

Ghost Tree Capital’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-450,000	Closed	-$3.02M	–	69
2024 Q1	$3.02M	Buy	450,000 +255,000	+131%	+$1.58M	0.84%	40
2023 Q4	$1.15M	Sell	195,000 -455,000	-70%	-$3.49M	0.37%	47
2023 Q3	$6.34M	Buy	650,000 +75,000	+13%	+$890K	2.08%	16
2023 Q2	$6.81M	Buy	575,000 +25,000	+5%	+$287K	2.25%	18
2023 Q1	$5.93M	Sell	550,000 -250,000	-31%	-$3.2M	1.75%	24
2022 Q4	$9.25M	Buy	800,000 +200,000	+33%	+$2.48M	3.95%	10
2022 Q3	$8.95M	Sell	600,000 -300,000	-33%	-$4.11M	2.51%	16
2022 Q2	$8.12M	Sell	900,000 -800,000	-47%	-$5.46M	4.23%	7
2022 Q1	$12.7M	Hold	1,700,000	–	–	2.76%	4
2021 Q4	$14.6M	Buy	1,700,000 +200,000	+13%	+$1.74M	5.23%	3
2021 Q3	$12.6M	Sell	1,500,000 -100,000	-6%	-$766K	3.69%	5
2021 Q2	$13M	Hold	1,600,000	–	–	3.57%	9
2021 Q1	$14M	Buy	1,600,000 +500,000	+45%	+$4.81M	3.3%	12
2020 Q4	$12.4M	Buy	+1,100,000	New	+$12.1M	2.75%	16

Other funds holding COGT

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Ghost Tree Capital's COGT Position: Q2 2024 in Review

Ghost Tree Capital sold out of Cogent Biosciences (COGT) in Q2 2024, closing a stake of 450,000 shares — an estimated $3.02M sold.

Ghost Tree Capital first reported a position in COGT in Q4 2020 and held it in 14 quarters. The position peaked at $14.6M in Q4 2021. 148 funds tracked by Wall St. Rank hold COGT as of Q2 2024.

Ghost Tree Capital reported no remaining Cogent Biosciences position as of Q2 2024 after selling out during the quarter.
Ghost Tree Capital sold 450,000 Cogent Biosciences shares in Q2 2024, an estimated $3.02M.
Ghost Tree Capital first reported a position in Cogent Biosciences in Q4 2020 and held it in 14 quarters.
Ghost Tree Capital's Cogent Biosciences position peaked at $14.6M in Q4 2021.
148 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2024.

Based on Ghost Tree Capital's 13F filing for Q2 2024, filed 14 Aug 2024.